GLP-1 therapies, including Ozempic, Wegovy, Mounjaro, and Zepbound, have gained popularity. However, their original purpose and effects on those who need them are not well understood. These therapies were initially developed to manage type 2 diabetes and obesity. Research has also shown potential in treating other conditions, such as sleep apnea, multiple sclerosis, and endometriosis.
Pharmaceutical marketing has contributed to the trend surrounding GLP-1s, focusing on weight loss. This has led to issues with affordable access for those who rely on these drugs. Further details on the impact of this trend and the original purpose of GLP-1 therapies are available.
The trend has raised concerns about the availability and marketing of these therapies, highlighting the need for a better understanding of their intended use and effects.
